Researchers at the University of Manitoba – Winnipeg and St. Boniface Hospital in Winnipeg have published the results of their research into a new antibiotic compound. This compound, referred to as PEG-2s, is novel in the way it ‘attacks’ infecting bacteria. Traditional antibiotics usually target a bacteria cell’s cell wall or its processes of DNA replication and protein synthesis. PEG-2s instead takes aim at one particular protein that is responsible for providing energy to the cell. The compound is so accurate and effective that the researchers claim that it does not have an effect on good gut bacteria or the body’s good cells. The protein that PEG-2S targets is not found in the normal cells of the body, and as such it could significantly mitigate any possible side effects. The researchers have successfully tested PEG-2S on legionella, other pneumonia bacteria, and the bacteria responsible for chlamydia. The tests have only been conducted within petri dishes, and as of now it has not been tested on animals or humans. The researchers see PEG-2S’s targeting system as providing a solution to the problem of antibiotic resistant bacteria because the drug acts so differently from traditional antibiotics that it would take a longer for bacteria to evolve any resistance mechanisms to it. The research team is currently in the process of seeking USDA approval.
Jules Zacher is an attorney in Philadelphia who has tried Legionnaires’ disease cases across the U.S. Please visit LegionnaireLawyer.com again for updates.